Institutional members access full text with Ovid®

Share this article on:

Genetic association study between methyl-CpG-binding domain genes and schizophrenia among Chinese family trios

Xie, Binga,d; Yu, Yaqina,b; Meng, Xiangfeia,b; Yu, Qionga,b; Shi, Jiepinga,b; Sang, Hongc; Kou, Changguia,b

doi: 10.1097/YPG.0000000000000042
Brief Reports

This study investigates the genetic association between methyl-CpG-binding domain (MBD) gene polymorphisms and schizophrenia. A total of 200 family trios consisting of fathers, mothers, and affected offspring with schizophrenia were recruited as our participants. Four tag SNPs on MBD1 (rs125555, rs140689, rs140687, and rs140686), three tag SNPs on MBD2 (rs3876254, rs7614, and rs1145317), and three tag SNPs on MBD3 (rs7252741, rs4807934, and rs4807122) genes were tested using the PCR-based ligase detection reaction (PCR-LDR). The transmission disequilibrium test showed that rs1145317 on the MBD2 gene was significantly overtransmitted from parents to schizophrenic offspring (P=0.026). The haplotype-based haplotype relative risk test revealed that the haplotype rs7614–rs1145317 (A–G) was associated with schizophrenia (P=0.029). Our finding suggests that the MBD2 gene may be a susceptibility gene for schizophrenia.

Supplemental Digital Content is available in the text.

aResearch Center for Genomic Medicine

bDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University

cChangchun Mental Health Hospital, Changchun

dCentral Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, China

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (

Correspondence to Changgui Kou, PhD, Research Center for Genomic Medicine, School of Public Health, Jilin University, 1163 Xinmin Street, Changchun 130021, Jilin, China Tel/fax: +86 0431 85619437; e-mail:

Received August 15, 2013

Accepted April 20, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins